Microsoft launches wearable fitness monitor; NuVasive hits 52-week high following earnings report;

@FierceMedDev: ICYMI: Diagnostic companies homing on on rapid mobile tests to quell Ebola outbreak. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Medtronic discloses new corporate structure upon Covidien deal close. Story | Follow @VarunSaxena2

@EmilyWFierce: Boston Scientific set to face first federal trials over transvaginal mesh products. Reuters article | Follow @EmilyWFierce

> Tech companies continue to venture into med tech, especially the wearable devices arena. Microsoft ($MSFT) launched Microsoft Band, a wrist-worn device with sensors that monitor pulse rate, calories burned and sleep quality. Story

> On Friday, shares in spinal implant device company NuVasive reached a 52-week high, as the company reported a loss of $1.8 million on sales of $189.9 million, $10 million higher than expected. News

> Sorin Group, a cardiovascular diseases device company, enrolled 1,039 patients with severe heart failure in a study testing the safety of the SonR cardiac resynchronization therapy (CRT) optimization system, which features a unique hemodynamic sensor. Release

Biotech News

@FierceBiotech: Nymox blasted as lead drug flops in twin PhIII enlarged prostate studies. News | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers beefs up fibrosis pipeline with $444M option deal. Report | Follow @JohnCFierce

@DamianFierce: $BMY gets into IPF with Galecto (and Magnus Persson, its fantastically named chairman) in a deal worth up to $444M. Release | Follow @DamianFierce

@EmilyMFierce: The planet's deadliest infectious diseases, by country. More via Salon | Follow @EmilyMFierce

> Geron shares rocket up after FDA takes the cuffs off its lead drug. Story

> $6B Covance buyout puts LabCorp in the CRO biz. Report

> Takeda drops a $750M schizophrenia drug pact with Intra-Cellular. Item

Pharma News

@FiercePharma: Tops this weekend: Express Scripts ready to favor AbbVie hep C prospect--provided it undercuts. Article | Follow @FiercePharma

@EricPFierce: The revamp continues at Takeda, as does its financial struggles. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Express Scripts ready to favor AbbVie hep C prospect--provided it undercuts Gilead. Story | Follow @CarlyHFierce

> Bristol-Myers' 91-country hep C access plan still draws fire from price critics. More

> AstraZeneca seals the deal for Almirall's respiratory meds. Article

CRO News

> PRA raises the stakes, eyeing $400M in a blockbuster IPO. More

> CRO Paragon raises $13M to expand its footprint. Story

> LabCorp is buying Covance for $5.6B to cut in on the CRO boom. News

> Timely deals boost Charles River's balance sheet. Story

> Quintiles posts another $1B quarter and dials up its expectations. Report

Biotech IT News

> Venter makes new hires at Synthetic Genomics and Human Longevity. Item

> Cleveland Clinic teams with IBM to use Watson in genomics cancer research. Report

> Report: GSK, J&J, Merck and Sanofi have made mobile app breakthroughs. More

> Novo Nordisk pushes back date of IT IPO decision to 2015. Story

> Boehringer picks IDBS system in consolidation of ELN. Article

Animal Health News

> IDEXX follows positive earnings with acquisition of Animana. Item

> Advaxis sees encouraging results for immuno-oncology treatment in dogs with bone cancer. Report

> Analysts to Heska: Why has strong performance been overlooked? Article

> Jaguar Animal Health trims IPO target number by 26%. More

> Possible threat to strong launch of Merial's anti-flea pill NexGard adds to Sanofi's woes. Story

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.